Agenus Inc (NAS:AGEN)
$ 15.56 0.43 (2.84%) Market Cap: 326.75 Mil Enterprise Value: 353.53 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 57/100

Agenus Inc. - Special Call Transcript

Jun 02, 2020 / 09:30PM GMT
Release Date Price: $79.88 (-4.01%)
Operator

Good afternoon, ladies and gentlemen, and welcome to the next-generation immuno-oncology therapeutics conference call. (Operator Instructions)

It is now my pleasure to turn the floor over to your host, Mayank Mamtani. Sir, the floor is yours.

Mayank Mamtani
B. Riley FBR, Inc., Research Division - Research Analyst

Thank you, John. Hello, good evening, everyone. This is Mayank Mamtani, I'm a senior analyst covering biotechnology companies at B. Riley FBR. I hope everyone is keeping well and thanks for joining. I'm pleased to welcome you to our expert panel call today to recap an exciting data at ASCO weekend, in particular focusing on next-generation CTLA-4 agents where we saw Agenus present encouraging early data as monotherapy and in combination with PD-1. We have with us on the call, Dr. Steven O'Day, who were the leading clinical investigator who presented that data, and also Dr. Charles Drake, who have -- and both of these guys had -- obviously don't need introduction, but they've obviously pioneered the checkpoint inhibitor biology space over the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot